Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures
Primary Purpose
Leg Ulcer
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Kerecis Omega 3
Surgical debridement
Sponsored by
About this trial
This is an interventional treatment trial for Leg Ulcer
Eligibility Criteria
Inclusion Criteria: Any chronic leg ulcer > 4 weeks duration with delayed wound healing (reduction of wound surface of less than 40-50% within 4 weeks under adequate local therapy) without underlying treatable medical conditions Ulcer area at between 5cm2 and 60cm2 Bacterial swab sampling prior to study Written study informed consent Exclusion Criteria: History of Fish allergy or proven Fish allergy Pregnant or breast-feeding women Intention to become pregnant during the course of the study Wound not suitable for dressing: inflammation, fibrin coatings Inability to understand the study consent
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Kerecis Omega 3
Surgical debridement
Arm Description
Outcomes
Primary Outcome Measures
Change in ulcer surface area
Change in ulcer surface area as assessed by standardized photography and digital imaging.
Secondary Outcome Measures
Change in patient quality of life
Change in patient quality of life as assessed by the Wound-QoL questionnaire score, ranging from 0 to 4, with higher scores indicating a worse quality of life.
Change in wound microbiota as assessed by alpha diversity of the microbial composition
Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by alpha diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species
Change in wound microbiota as assessed by beta diversity of the microbial composition
Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by beta diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species.
Change in ulcer surface area
Change in ulcer surface area as assessed by standardized photography and digital imaging.
Full Information
NCT ID
NCT06036485
First Posted
March 15, 2023
Last Updated
September 6, 2023
Sponsor
Insel Gruppe AG, University Hospital Bern
1. Study Identification
Unique Protocol Identification Number
NCT06036485
Brief Title
Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures
Official Title
Efficacy of Kerecis Omega 3 Versus Standard of Care in Patients With Chronic Leg Ulcerations - a Randomized Trial With a New In-wound Split Design Approach
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Lack of funding to support the study
Study Start Date
May 1, 2023 (Actual)
Primary Completion Date
May 1, 2023 (Actual)
Study Completion Date
May 1, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Chronic leg ulcerations are a great burden for patients and the medical system alike. Frequent outpatient consultations with associated treatment costs and travel costs for the patient as well as psychosocial burdens remain an unmet problem in chronic wound care. There is an increasing need for definitive treatment of especially chronic venous and multifactorial chronic leg ulceration where arterial intervention is not a treatment option.
Minimal invasive surgical interventions that do not require skin grafting can be performed under local anesthesia in an outpatient setting even in multimorbid patients.
Kerecis Omega3 Wound is intact decellularized fish skin. The fish skin sheets contain fat, protein, elastin, glycans and other natural skin elements and it can be an effective treatment option in chronic leg ulcerations and is licensed for this use as a medical product in Switzerland. However, limited data without inter-wound bias is available for the use of Kerecis Omega 3 in chronic leg ulcerations.
In this study the investigators propose to investigate the efficacy of Kerecis Omega 3 according to objective wound surface measurements using standardized digital photographs in patients with chronic leg ulcerations. Efficacy will be evaluated against standard of care wound debridement.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leg Ulcer
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
1:1 in-wound split design with random allocation
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Kerecis Omega 3
Arm Type
Experimental
Arm Title
Surgical debridement
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Kerecis Omega 3
Intervention Description
Decellularized intact fish skin developed for the management of chronic wounds
Intervention Type
Procedure
Intervention Name(s)
Surgical debridement
Intervention Description
Superficial sharp surgical debridement technique
Primary Outcome Measure Information:
Title
Change in ulcer surface area
Description
Change in ulcer surface area as assessed by standardized photography and digital imaging.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in patient quality of life
Description
Change in patient quality of life as assessed by the Wound-QoL questionnaire score, ranging from 0 to 4, with higher scores indicating a worse quality of life.
Time Frame
2, 4, 6 and 12 weeks
Title
Change in wound microbiota as assessed by alpha diversity of the microbial composition
Description
Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by alpha diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species
Time Frame
2, 4, 6 and 12 weeks
Title
Change in wound microbiota as assessed by beta diversity of the microbial composition
Description
Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by beta diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species.
Time Frame
2, 4, 6 and 12 weeks
Title
Change in ulcer surface area
Description
Change in ulcer surface area as assessed by standardized photography and digital imaging.
Time Frame
2, 4, 6 and 12 weeks
Other Pre-specified Outcome Measures:
Title
Incidence of adverse events
Description
Cumulative incidence of treatment-related adverse events
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Any chronic leg ulcer > 4 weeks duration with delayed wound healing (reduction of wound surface of less than 40-50% within 4 weeks under adequate local therapy) without underlying treatable medical conditions
Ulcer area at between 5cm2 and 60cm2
Bacterial swab sampling prior to study
Written study informed consent
Exclusion Criteria:
History of Fish allergy or proven Fish allergy
Pregnant or breast-feeding women
Intention to become pregnant during the course of the study
Wound not suitable for dressing: inflammation, fibrin coatings
Inability to understand the study consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simon Bossart, MD
Organizational Affiliation
Department of dermatology, University Hospital Inselspital, Bern
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures
We'll reach out to this number within 24 hrs